Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Earnings of -$0.20 Per Share

Equities analysts predict that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce earnings per share of ($0.20) for the current quarter, according to Zacks. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.18). AcelRx Pharmaceuticals reported earnings of ($0.21) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 4.8%. The firm is expected to report its next earnings results on Thursday, March 1st.

On average, analysts expect that AcelRx Pharmaceuticals will report full-year earnings of ($1.07) per share for the current fiscal year, with EPS estimates ranging from ($1.14) to ($0.98). For the next fiscal year, analysts expect that the firm will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.07) to ($0.85). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover AcelRx Pharmaceuticals.

Several equities research analysts have commented on the stock. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Jefferies Group downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. Royal Bank of Canada reduced their target price on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, October 13th. Piper Jaffray Companies reissued a “hold” rating and set a $2.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, October 13th. Finally, Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research report on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. AcelRx Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.18.

AcelRx Pharmaceuticals (NASDAQ:ACRX) traded up $0.12 during trading hours on Friday, reaching $2.18. 778,295 shares of the company’s stock traded hands, compared to its average volume of 432,466. The company has a debt-to-equity ratio of -0.43, a quick ratio of 4.71 and a current ratio of 4.78. The stock has a market cap of $103.19, a price-to-earnings ratio of -1.94 and a beta of 2.96. AcelRx Pharmaceuticals has a 52-week low of $1.55 and a 52-week high of $5.75.

In related news, Director Mark G. Edwards bought 30,000 shares of AcelRx Pharmaceuticals stock in a transaction dated Tuesday, November 14th. The stock was purchased at an average cost of $1.90 per share, with a total value of $57,000.00. Following the transaction, the director now directly owns 150,000 shares of the company’s stock, valued at $285,000. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 28.10% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACRX. Perennial Advisors LLC bought a new position in AcelRx Pharmaceuticals in the 3rd quarter worth approximately $138,000. Virtu KCG Holdings LLC boosted its holdings in AcelRx Pharmaceuticals by 600.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares during the period. Geller Family Office Services LLC bought a new position in AcelRx Pharmaceuticals in the 3rd quarter worth approximately $460,000. Finally, Goldman Sachs Group Inc. bought a new position in AcelRx Pharmaceuticals in the 2nd quarter worth approximately $530,000. 13.70% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Earnings of -$0.20 Per Share” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/06/zacks-analysts-expect-acelrx-pharmaceuticals-inc-acrx-will-announce-earnings-of-0-20-per-share.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply